The Department of Health and Human Services Office of the Assistant Secretary for Preparedness & Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA) has awarded a cost-sharing contract to GlaxoSmithKline for advanced development of a transient receptor potential cation channel V4 (TRPV4) antagonist as a novel medical countermeasure for acute respiratory distress syndrome due to chlorine gas inhalation.

BARDA provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.

The award is valued at $61,740,781 and was made under BARDA-CBRN-BAA-16-100-SOL-00001.